How is the CSL (ASX: CSL) share price performing in the age of Omicron?

The last few months have been tough for the biotech giant.

| More on:
a medical person in protective clothing, rubber gloves, a mask and hair covering holds a digital thermometer up to the front of the picture as if to take someone's temperature.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price has slumped 13% since the Omicron variant emerged
  • The dip was likely mostly driven by its acquisition of Vifor Pharma and subsequent capital raise
  • Previously, the biotechnology company's stock has weathered the pandemic reasonably well

While the COVID-19 pandemic wreaked havoc on many ASX stocks, the CSL Limited (ASX: CSL) share price has traded relatively flat throughout the period.

Of course, sentiment for the company was likely boosted by its manufacturing of the AstraZeneca (NYSE: AZN) COVID-19 vaccine. Though, it was hindered by the impact the pandemic has had on plasma collections.

Despite a rocky performance, the CSL share price gained around 2% over the course of 2020 and was boosted another 2% last year.

For context, the S&P/ASX 200 Index (ASX: XJO) fell 3% in 2020 and gained 13% in 2021.

At the time of writing, the CSL share price is $272.19, a fall of 0.56% in early trading.

Let's take a look at how the biotechnology giant's stock has been performing since the Omicron variant emerged.

How has the CSL share price traded since Omicron emerged?

The discovery of COVID-19's Omicron variant was first announced to the world on 25 November.

Then, South Africa's National Institute for Communicable Diseases announced it had identified a then-unnamed variant responsible for just 22 infections in the nation.

Of course, the variant soon reached Australia and the rest is history. But there's hope we might be out of the woods sooner rather than later.

Federal health minister Greg Hunt said on Sunday, the current Omicron outbreak may be peaking in New South Wales and the ACT and the rest of the country will likely follow suit in coming weeks.

Since news of the Omicron variant's emergence, the CSL share price has tumbled 13%. Though, it hasn't simply been the new virus strain weighing it down.

It announced a massive US$12 billion takeover after close on 14 December. The biotechnology giant will be purchasing Vifor Pharma, a Swiss pharmaceutical company specialising in the treatment of iron deficiency.

Unfortunately, the market didn't react favourably to the news. It sent the CSL share price tumbling 8% after the company exited a trading halt put in place as it underwent a $6.3 billion capital raise.

While the stock mostly recovered over following sessions, it has slumped another 6% year to date.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »